- Home
- BMEA vs VERU Comparison
BMEA vs VERU Comparison
Compare BMEA & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- VERU
- Stock Information
- Founded
- BMEA 2017
- VERU 1971
- Country
- BMEA United States
- VERU United States
- Employees
- BMEA N/A
- VERU N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- BMEA Health Care
- VERU Health Care
- Exchange
- BMEA Nasdaq
- VERU Nasdaq
- Market Cap
- BMEA 65.8M
- VERU 76.9M
- IPO Year
- BMEA 2021
- VERU 1990
- Fundamental
- Price
- BMEA $1.44
- VERU $0.51
- Analyst Decision
- BMEA Strong Buy
- VERU Strong Buy
- Analyst Count
- BMEA 11
- VERU 2
- Target Price
- BMEA $27.60
- VERU $4.00
- AVG Volume (30 Days)
- BMEA 703.1K
- VERU 3.3M
- Earning Date
- BMEA 05-05-2025
- VERU 05-08-2025
- Dividend Yield
- BMEA N/A
- VERU N/A
- EPS Growth
- BMEA N/A
- VERU N/A
- EPS
- BMEA N/A
- VERU N/A
- Revenue
- BMEA N/A
- VERU $16,886,419.00
- Revenue This Year
- BMEA N/A
- VERU N/A
- Revenue Next Year
- BMEA N/A
- VERU N/A
- P/E Ratio
- BMEA N/A
- VERU N/A
- Revenue Growth
- BMEA N/A
- VERU 134.43
- 52 Week Low
- BMEA $1.29
- VERU $0.45
- 52 Week High
- BMEA $13.07
- VERU $1.42
- Technical
- Relative Strength Index (RSI)
- BMEA 39.69
- VERU 47.70
- Support Level
- BMEA $1.29
- VERU $0.48
- Resistance Level
- BMEA $1.52
- VERU $0.67
- Average True Range (ATR)
- BMEA 0.14
- VERU 0.04
- MACD
- BMEA 0.01
- VERU 0.00
- Stochastic Oscillator
- BMEA 28.17
- VERU 14.84
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.